Entrada Therapeutics, Inc. Common Stock
Compare this stock
TRDA Stock Report Card
$
27%
Performance
Score:
10/100
TRDA returned -10.07% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.
Technicals
Score:
71/100
TRDA receives a 71 of 100 based on 14 indicators. 9 are bullish, 3 are bearish.
Earnings
Score:
10/100
TRDA has missed earnings 4 times in the last 20 quarters.
Profit
Score:
10/100
Out of the last 13 quarters, TRDA has had 1 profitable quarters and has increased their profits year over year on 1 of them.
Volatility
Score:
51/100
TRDA has had a higher than average amount of volatility over the last 12 months giving it a score of 50 of 100.
Entrada Therapeutics, Inc. Common Stock Summary
Nasdaq / TRDA
Healthcare
Biotechnology
Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Checkout Similar Companies
TRDA scored poorly on our reportcard. Here are some similar companies and how they performed.
